ZLAB - Zai Lab Ltd Stock Price, Fair Value and News

$20.53-0.08 (-0.39%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ZLAB RSI Chart

ZLAB Valuation

Market Cap

20.1B

Price/Earnings (Trailing)

-67.54

Price/Sales (Trailing)

62.43

EV/EBITDA

-67.89

Price/Free Cashflow

-97.73

ZLAB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ZLAB Fundamentals

ZLAB Revenue

Revenue (TTM)

322.7M

Rev. Growth (Yr)

45.95%

Rev. Growth (Qtr)

15.32%

ZLAB Earnings

Earnings (TTM)

-298.3M

Earnings Growth (Yr)

33.6%

Earnings Growth (Qtr)

-50.13%

ZLAB Price Action

Last 7 days

3.4%

Last 30 days

26.3%

Last 90 days

9.8%

Trailing 12 Months

-19.7%

ZLAB Profitability

Operating Margin

66.50%

EBT Margin

-92.44%

Return on Equity

-42.37%

Return on Assets

-30.21%

Free Cashflow Yield

-1.02%

ZLAB Financial Health

Current Ratio

3.46

ZLAB Investor Care

Shares Dilution (1Y)

1.72%

Diluted EPS (TTM)

-0.3

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	291.1M	322.7M	0	0
2023	231.1M	251.8M	263.5M	266.7M
2022	170.9M	182.2M	196.6M	215.0M
2021	60.8M	86.8M	115.2M	144.3M
2020	20.9M	28.8M	38.5M	49.0M
2019	0	0	0	13.0M
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Zai Lab Ltd

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naÃƒÆ’Ã‚Â¯ve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

CEO	Dr. Ying Du Ph.D.
WEBSITE	zailaboratory.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	2036

Zai Lab Ltd Frequently Asked Questions

What is the ticker symbol for Zai Lab Ltd? What does ZLAB stand for in stocks?

ZLAB is the stock ticker symbol of Zai Lab Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zai Lab Ltd (ZLAB)?

As of Fri Sep 13 2024, market cap of Zai Lab Ltd is 20.15 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZLAB stock?

You can check ZLAB's fair value in chart for subscribers.

Is Zai Lab Ltd a good stock to buy?

The fair value guage provides a quick view whether ZLAB is over valued or under valued. Whether Zai Lab Ltd is cheap or expensive depends on the assumptions which impact Zai Lab Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZLAB.

What is Zai Lab Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Sep 13 2024, ZLAB's PE ratio (Price to Earnings) is -67.54 and Price to Sales (PS) ratio is 62.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZLAB PE ratio will change depending on the future growth rate expectations of investors.